A new study shows that combining size-based and count-based analysis helps determine whether a copy number aberration originates in the mother, fetus, or both.
The company plans to launch the new qNIPT test, which uses methylation-specific quantitative PCR to detect fetal epigenetic biomarkers, in the near future.
The company has also expanded its current Veracity NIPT to sex chromosomal aneuplodies and twin pregnancies, and plans to offer microdeletion testing next year.
By offering NIPT as a secondary screening test, the UK hopes to reduce the number of invasive diagnostic tests and associated miscarriages.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
ACMG said in a position statement that NIPS can replace conventional screening for Patau, Edwards, and Down syndrome in most women.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Last month, the foundation, in partnership with the Washington State Department of Health, released seven educational videos about prenatal testing.
A re-analysis of non-invasive prenatal testing data from CARE found fewer false-positive cases caused by maternal copy number variants and other factors.
Based on data from more than 6,000 clinical cases, the investigators from Switzerland advocated for an expansion of NIPT to cover additional alterations and associated phenotypes.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.